Pioneering a New Class of Vaccines for Global Unmet Medical Needs
Constantly-Mutating Global Infectious Diseases
Osivax is rapidly expanding its oligoDOM® based pipeline, with the following candidates currently in development: a universal influenza vaccine (OVX836) and a sarbecovirus vaccine (OVX033), as well as a pan-strain human papillomavirus vaccine (PANHPVAX).
Multiple combination opportunities
OVX836 – Universal Flu Vaccine Candidate
Facts about the
Influenza is a devastating disease, with routine global outbreaks that pose a profound threat to global health. Seasonal influenza kills hundreds of thousands of people annually and pandemic influenza can cause tens of millions of deaths as demonstrated by historic outbreaks.
by flu every season worldwide
emergence of a pandemic strain
within 6 months of time.
Current seasonal flu vaccines are only partially effective because they target strain-specific surface antigens, which mutate at high rates and thus change seasonally. A universal vaccine presents the highly needed opportunity to provide broad coverage across all seasonal and pandemic strains.
Osivax is creating a revolutionary universal influenza vaccine which will uniquely empower both the B-cell immune response and the T-cell immune response. Osivax will combine its best-in-class T-cell component (OVX836) with conventional flu vaccines to fully empower both arms of the immune system.
OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, the NP is much less likely to mutate, alleviating the need for annual vaccination updates. Osivax’ oligoDOM® technology enables the transformation of the NP into a highly immunogenic antigen to trigger powerful T-cell immune responses.
Osivax’ lead candidate has shown powerful and long-lasting systemic and local immune responses in preclinical development. In vivo, it has shown strong efficacy against both A and B strain flu viruses and an excellent safety profile in a GLP toxicology study. After successful Phase 1 and Phase 2a clinical trials, OVX836 is currently being evaluated in a multicentric combination trial with conventional flu vaccines in Australia.
OVX033 – Universal Sarbecovirus Vaccine Candidate
Facts about the
over the past 20 years
Currently commercialized vaccines target the constantly evolving spike surface antigens with the aim to generate B-cell responses. Osivax is creating a revolutionary universal sarbecovirus vaccine which will uniquely empower both the B-cell immune response and the T-cell immune response.
Osivax is engineering a vaccine (OVX033) that targets the virus’ nucleocapsid, an internal and invariant antigen. This target can be transformed into a highly immunogenic antigen when enabled by the oligoDOM® technology and is expected to provide universal breadth of protection against all current and future sarbecoviruses.
Osivax builds on the experience gained through the development of OVX836 in influenza which helped facilitate the development and drive of OVX033 to preclinical proof-of-concept in less than one year.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 961112. This project is supported by the French State, through the Banque Publique d’Investissement (BPI) France’s program: Programme d’investissements d’avenir and France 2030.